Search results
Your search for ������������������������������:kn39������������������������,������24������,������������������������,���������������������,��������������� returned no results
Showing 1 to 15 of 358 results for ������������������������������:know������������������������,������24������,������������������������,���������������������,���������������
Showing 1 to 15 of 358 results for ������������������������������:know������������������������,������24������,������������������������,���������������������,���������������
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients.
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.